LUMICKS
@lumicks.bsky.social
Empowering scientists with tools that reveal crucial insights not available before, at the molecular and cellular level | Dynamic single-molecule & Cell Avidity
Are you working on cell therapy? Looking for a reliable indicator to predict patient outcomes from preclinical immune assays?
👉 Last chance to register for LIVE webinar by Prof. Peter Chockley on how Cell Avidity measurements predict leukemia patient survival after transplant: bit.ly/3JHMzou
👉 Last chance to register for LIVE webinar by Prof. Peter Chockley on how Cell Avidity measurements predict leukemia patient survival after transplant: bit.ly/3JHMzou
November 17, 2025 at 1:52 PM
Are you working on cell therapy? Looking for a reliable indicator to predict patient outcomes from preclinical immune assays?
👉 Last chance to register for LIVE webinar by Prof. Peter Chockley on how Cell Avidity measurements predict leukemia patient survival after transplant: bit.ly/3JHMzou
👉 Last chance to register for LIVE webinar by Prof. Peter Chockley on how Cell Avidity measurements predict leukemia patient survival after transplant: bit.ly/3JHMzou
TODAY: Discover how Prof. Taekjip Ha (Harvard University) used the LUMICKS C-Trap to uncover real-time dynamics of chromatin remodelers and transcription factors at the single-molecule level.
Join the webinar: bit.ly/3VdxuNs
Join the webinar: bit.ly/3VdxuNs
September 10, 2025 at 12:27 PM
TODAY: Discover how Prof. Taekjip Ha (Harvard University) used the LUMICKS C-Trap to uncover real-time dynamics of chromatin remodelers and transcription factors at the single-molecule level.
Join the webinar: bit.ly/3VdxuNs
Join the webinar: bit.ly/3VdxuNs
The scientific community responded with fantastic curiosity to Avidion at AACR, and we couldn’t be more confident about the future of Cell Avidity in cell and antibody therapy. A great success!
(Still) curious? 👉 Discover more on the Avidion page: lumicks.com/avidion
(Still) curious? 👉 Discover more on the Avidion page: lumicks.com/avidion
May 7, 2025 at 1:08 PM
The scientific community responded with fantastic curiosity to Avidion at AACR, and we couldn’t be more confident about the future of Cell Avidity in cell and antibody therapy. A great success!
(Still) curious? 👉 Discover more on the Avidion page: lumicks.com/avidion
(Still) curious? 👉 Discover more on the Avidion page: lumicks.com/avidion